MedTrace Logo

SPECT Imaging of DAT Genotype

NCT01492322 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 14

Last updated 2015-10-12

No results posted yet for this study

Summary

A polymorphism in the dopamine transporter (DAT) may determine how much dopamine is available at the synapse and this may affect the underlying reasons for relapse in smokers. This research will use Single-photon emission computed tomography SPECT and the DAT-specific ligand, TRODAT (Dopamine Transporter Density by \[99mTc\]), to examine the availability of DAT in smokers grouped by genotype in the sated (just having smoked) and withdrawal (4 hours without smoking) conditions.

Conditions

  • Nicotine Withdrawal

Interventions

RADIATION

TRODAT

Smoker will receive a TRODAT injection

Sponsors & Collaborators

Principal Investigators

  • Teresa Franklin, PhD · University of Pennsylvania

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2013-07-31
Completion
2014-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01492322 on ClinicalTrials.gov